Director of Research
Keyun has a broad background in molecular biology and virology, with specific training and expertise in areas related to gene therapy using recombinant adeno-associated virus (AAV) vectors. As a postdoctoral fellow at the Indiana University School of Medicine, he focused on the study of the molecular biology of AAV in Dr. Arun Srivastava’s laboratory, where he made a number of seminal discoveries. These studies also resulted in the development of novel recombinant AAV vectors for efficient gene transfer in different cell lines in vitro and in animal models in vivo.
Following a brief stint as a junior faculty member in the Department of Microbiology and Immunology at Indiana University School of Medicine, where he was involved in training a number of postdoctoral fellows, graduate students, and research staff, he accepted a position as a Scientist at Eli Lilly and Company, where he worked for over sixteen years. In Lilly research laboratory, Keyun focused on the studies of recombinant AAV vectors expressing several peptides and neuropeptides, respectively, in disease models leading to development of medicine in the field of type II diabetes and obesity/ metabolic syndrome. In late 2017, Keyun opted for early retirement from Eli Lilly, and joined aaVective as Director of Research, where he has assumed a leadership role in supervising all research personnel. He is also a co-founder of an AAV gene therapy company, KASHX Bio, which was launched in 2018.
Keyun obtained his MD and MSc degrees in 1985 and 1988, respectively, from the prestigious Hunan Medical College in Changsha, China.